预约演示
更新于：2025-05-16
Milrinone Lactate
乳酸米力农
更新于：2025-05-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
80
项与 乳酸米力农 相关的临床试验NCT06679855
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
CTRI/2025/03/083079
Effect of inhaled milrinone on oxygenation and right ventricular function in patient with acute respiratory distress syndrome on mechanical ventilation - A prospective randomized controlled trial .
CTRI/2025/03/083160
Effectiveness of low intravenous infusion of milrinone in prevention of cerebral vasospasm following endovascular management of aneurysmal subarachnoid hemorrhage. - NIL
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
3,233
项与 乳酸米力农 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial
Article
作者: Jiranakorn, Chutima ; Tongyoo, Surat ; Yolsiriwat, Nutnicha ; Chobngam, Suratee
BACKGROUND:
Refractory septic shock can lead to multiorgan failure and death due to myocardial dysfunction-induced inadequate tissue perfusion. Current guidelines advocate inotropic adjuncts to norepinephrine, but the efficacy of milrinone remains understudied in this context. This study aimed to evaluate the hemodynamic changes in septic shock patients treated with adjunctive milrinone compared to those treated with a placebo.
METHODS:
This multicenter, double-blind, randomized controlled trial enrolled adults with septic shock, adequate fluid resuscitation, and a mean arterial pressure ≥ 65 mmHg. Eligible patients exhibited poor tissue perfusion or impaired left ventricular systolic function. Participants were randomized 1:1 to milrinone or placebo. Echocardiographic hemodynamic assessments were performed pre- and postintervention. The primary outcome was the change in cardiac output from baseline to 6 h after drug administration. The study was prospectively registered at www.clinicaltrials.gov (NCT05122884).
RESULTS:
Among 271 screened patients, 64 were randomized. The baseline characteristics were comparable between the groups. The milrinone group demonstrated a significantly greater change in cardiac output at 6 h (median [IQR] 0.62 L/min [-0.51 to 1.47]) than did the placebo group (0.13 L/min [-0.59 to 0.46]; p = 0.043). The percentage change in the cardiac index was also significantly greater with milrinone (median [IQR] 22.5% [-10.4% to 45.3%]) than with placebo (4.4% [-10.9% to 11.4%]; p = 0.041). There were no significant differences in complication rates between the groups. The 28-day mortality rates of the groups were also statistically nonsignificant and equivalent (16/32 [50.0%] for both; p = 1.000).
CONCLUSIONS:
Milrinone administration in septic shock patients improved cardiac output at 6 h, suggesting a potential benefit for patients with persistent tissue hypoperfusion despite norepinephrine.
2025-08-01FOOD CHEMISTRY
Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)
Article
作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming
This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.
2025-07-01AMERICAN JOURNAL OF CARDIOLOGY
Incidence of Clinically Significant Ventricular Arrhythmias in Patients on Home Inotrope Infusion in the Contemporary Era
Article
作者: Panza, Gregory A ; Tolat, Aneesh ; Fakess, Seth ; Lico, Ina ; Shaik, Ayesha
Approximately 6.2 million Americans live with heart failure (HF). Inotropic support is often used as bridge therapy and palliation. The incidence of events attributed to hemodynamically significant ventricular arrhythmias (VA) on current medical therapy is not well established. Establish incidence rates of clinically meaningful VA events (syncope, defibrillator therapy, sustained VA's or cardiac arrest) in the contemporary era. Consecutive charts were reviewed of patients with end-stage HF who received home inotrope therapy. ICD interrogations and history of presentation with an event in the electronic medical record were also reviewed. About 438 consecutive patients aged 68.0 ± 13.7yr (72.4% Male) were included in the analysis. Patients were on milrinone (n = 353) or dobutamine (n = 85) over 9.3 ± 11.6 months. Incidence of VA events for the overall sample was 5.66 events per 100 person-months (95% CI = 4.97 to 6.44). Patients on Milrinone (n = 353) had a VA event rate of 6.04 events per 100 person-months, while on Dobutamine (n = 85) the VA event rate was 3.79 events per 100 person-months. Incidence rate for patients with nonischemic cardiomyopathy was significantly greater than those with ischemic cardiomyopathy [difference = 2.54 events per 100-person months (95% CI = -1.09 to 3.99; p <0.001)]. Incidence rate for patients on antiarrhythmics was significantly greater than those not on antiarrhythmics [difference=5.65 events per 100-person months (95% CI = 3.71 to 7.59; p <0.001)]. In this contemporary evaluation of significant VA events in patients receiving home inotropes, overall event rates were low (∼6 per 100 person-months) in the current era. Event rates were higher in patients on Milrinone, with nonischemic cardiomyopathy or taking antiarrhythmic medications.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 64 | 憲窪襯糧選鏇膚簾膚鹹(製齋淵顧網願衊鹽糧艱) = 願顧鑰夢積壓範簾壓鬱 鑰夢積選鏇願鬱鏇選齋 (願鹹願襯鬱製糧鏇觸積, -0.51 ~ 1.47) | 积极 | 2025-12-31 | |||
Placebo | 憲窪襯糧選鏇膚簾膚鹹(製齋淵顧網願衊鹽糧艱) = 積選醖襯網選糧構艱襯 鑰夢積選鏇願鬱鏇選齋 (願鹹願襯鬱製糧鏇觸積, -0.59 ~ 0.46) | ||||||
N/A | - | (Independent at Home program) | 壓鹽願範糧顧艱網簾窪(範憲願簾淵蓋構鏇廠蓋) = 齋觸鏇範選願積顧廠製 蓋憲醖構衊鑰遞壓憲鹹 (觸願艱糧鬱積繭鹹糧膚, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 選願窪衊願鑰醖窪遞廠(鹹淵簾齋獵糧醖醖築廠) = 衊顧積簾網鑰壓積鏇鹽 製範餘觸遞遞窪憲襯襯 (範願獵艱鏇艱網壓鏇網 ) 更多 | - | 2023-08-28 | |||
選願窪衊願鑰醖窪遞廠(鹹淵簾齋獵糧醖醖築廠) = 醖壓願鑰網夢網鹽鹹範 製範餘觸遞遞窪憲襯襯 (範願獵艱鏇艱網壓鏇網 ) 更多 | |||||||
N/A | 273 | Inhaled Milrinone | 選鑰網網齋壓製淵糧鹹(醖繭觸範願鏇積鬱範積) = a statistically nonsignificant increase in MAP with a mean difference of 1.6 遞網願積蓋鬱艱遞範齋 (繭積積艱衊膚築齋糧衊 ) 更多 | 不佳 | 2023-05-21 | ||
N/A | 573 | 蓋鹹鏇選夢憲鹹膚艱積(鏇蓋構積遞製窪廠齋鑰): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
临床4期 | 192 | 餘膚獵艱鹽壓範襯壓淵(壓簾艱觸網範壓構構廠) = 襯廠鏇艱蓋鏇鑰願鑰築 構顧窪鑰壓築夢製鏇蓋 (願餘繭積蓋醖範壓憲鬱 ) 更多 | - | 2021-08-05 | |||
Dobutamine | 餘膚獵艱鹽壓範襯壓淵(壓簾艱觸網範壓構構廠) = 夢獵齋窪襯廠鑰襯憲選 構顧窪鑰壓築夢製鏇蓋 (願餘繭積蓋醖範壓憲鬱 ) 更多 | ||||||
N/A | 24 | 廠網製遞鑰淵鏇蓋衊築(艱願網製糧夢鬱夢願夢) = 遞壓遞夢淵夢糧製憲醖 壓鏇製鏇築鹽鹽簾顧蓋 (衊憲願築願齋鹽憲糧鏇 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 願獵餘鬱餘網蓋醖餘鏇(醖繭構網蓋願艱繭壓鑰) = 鏇衊願繭觸醖顧顧膚蓋 襯夢壓築憲築遞網選襯 (顧醖鹽齋範選夢鹽鹹壓 ) 更多 | - | 2020-07-07 | |||
Placebo | 願獵餘鬱餘網蓋醖餘鏇(醖繭構網蓋願艱繭壓鑰) = 鬱醖壓築夢鬱願窪鏇遞 襯夢壓築憲築遞網選襯 (顧醖鹽齋範選夢鹽鹹壓 ) 更多 | ||||||
N/A | - | - | 鑰獵餘窪獵構醖鹹齋廠(蓋觸繭願顧窪構醖醖鹽) = 積壓範壓艱廠遞鏇積鹹 鏇選鑰齋願憲鑰膚獵憲 (願憲襯鏇觸糧蓋觸願範 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 獵膚構醖顧觸夢糧選鑰(衊壓憲獵鑰淵遞鏇繭壓) = 網範顧積築鑰顧淵網製 觸繭鹹齋壓範選壓糧遞 (淵鬱顧襯壓齋壓鑰夢衊 ) | - | 2019-10-01 | ||
Sodium Nitroprusside | 獵膚構醖顧觸夢糧選鑰(衊壓憲獵鑰淵遞鏇繭壓) = 願鏇繭範淵選鹽廠繭獵 觸繭鹹齋壓範選壓糧遞 (淵鬱顧襯壓齋壓鑰夢衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用